The latest Investing Matters Podcast with Jean Roche, Co-Manager of Schroder UK Mid Cap Investment Trust has just been released. Listen here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksGlaxosmithkline Share News (GSK)

Share Price Information for Glaxosmithkline (GSK)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 1,786.00
Bid: 1,785.50
Ask: 1,786.00
Change: 8.00 (0.45%)
Spread: 0.50 (0.028%)
Open: 1,780.00
High: 1,793.50
Low: 1,766.50
Prev. Close: 1,778.00
GSK Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Monday broker round-up UPDATE

Mon, 22nd Apr 2013 07:20

Admiral Group: Deutsche Bank takes target price from 1140p to 1300p retaining a hold recommendation.African Barrick Gold: Deutsche Bank ups target price from 173p to 180p staying with its hold recommendation.Albemarle & Bond: Canaccord Genuity reduces target price from 280p to 146p and downgrades from a speculative buy to hold.Anglo American: Deutsche Bank cuts target price from 2210p to 2170p, while its buy recommendation remains unaltered. HSBC Holdings moves target price from 2240p to 2250p and maintains an overweight rating.Antofagasta: HSBC Holdings moves target price from 1160p to 1080p and reiterates a neutral rating.AstraZeneca: Credit Suisse increases target price from 3050p to 3130p and maintains an underperform rating.BHP Billiton: HSBC Holdings reduces target price from 2250p to 2110p, while upgrading to overweight. Espirito Santo cuts target price from 1703p to 1605p, while upgrading to neutral.Brooks Macdonald: Canaccord Genuity revises target price from 1540p to 1620p keeping a buy recommendation.Brown (N) Group: HSBC Holdings takes target price from 430p to 485p and retains an overweight rating.Burford Capital: Espirito Santo revises target price from 149p to 140p and stays with its buy recommendation.Cable & Wireless Communications: Jefferies shifts target price from 40p to 42p and retains a hold recommendation.Chariot Oil & Gas: UBS cuts target price from 70p to 20p downgrading from buy to neutral.Electrocomponents: Goldman Sachs reduces target price from 311p to 277p and downgrades to neutral.Eurasian Natural Resources: Exane BNP raises target price from 270p to 320p staying with a neutral rating.GlaxoSmithKline: Credit Suisse increases target price from 1450p to 1670p and reiterates its neutral rating.Hansteen Holdings: Espirito Santo lowers target price from 76p to 85p maintaining a neutral rating.Ithaca Energy: Westhouse Securities ups target price from 165p to 200p and reiterates a buy recommendation. RBC Capital increases target price to 225p and keeps an outperform rating.Kazakhmys: Credit Suisse upgrades from underperform to neutral with its target price at 450p. Exane BNP increases target price from 350p to 390 upgrading to neutral.Legal & General Group: Deutsche Bank ups target price from 170p to 189p keeping a buy recommendation.Lloyds Banking Group: RBC Capital shifts target price from 69p to 65p and reiterates an outperform rating.NetDimensions: Sanlam Securities restarts with a target price of 80p and a buy recommendation.New World Resources: Exane BNP cuts target price from 180p to 165p and leaves its underperform rating unchanged.Premier Farnell: Goldman Sachs lowers target price from 240p to 226p and downgrades to neutral.Prudential: Deutsche Bank increases target price from 1060p to 1240p maintaining its buy recommendation.Reckitt Benckiser: Canaccord Genuity takes target price from 3425p to 4100p, but still recommends selling.Regus: JP Morgan shifts target price from 135p to 140p, while downgrading to underweight.Rentokil Initial: Deutsche Bank moves target price from 76p to 100p reiterating a hold recommendation.Resolution: Deutsche Bank lowers target price from 285p to 273p and keeps a hold recommendation.Rio Tinto: HSBC Holdings cuts target price from 4180p to 4160p, while its overweight rating remains unchanged. Espirito Santo raises target price from 2910p to 3160p and upgrades to neutral.Sagentia Group:Westhouse Securities downgrades from add to neutral with a target price of 107p.Segro: Espirito Santo shifts target price from 247p to 250p and leaves its neutral rating unchanged.Spectris: Goldman Sachs cuts target price from 3250p to 2850p maintaining a strong buy recommendation. Credit Suisse reduces target price from 2670p to 2350p and retains an outperform rating. UBS takes target price from 2700p to 2500p, while leaving its buy recommendation unchanged. Bank of America moves target price from 2080p to 1980p and keeps an underperform rating. JP Morgan reduces target price from 2575p to 2455p, while its overweight rating remains unchanged.Spirent Communications: Jefferies reduces target price from 196p to 140p keeping a buy recommendation. Investec places its target price (prev. 175p) under review reiterating its buy recommendation. Canaccord Genuity lowers target price from 135p to 120p and retains a hold recommendation.St James's Place: Deutsche Bank raises target price from 485p to 525p, while keeping a hold recommendation.Sweett Group: WH Ireland shifts target price from 27p to 33p and moves from a speculative buy to a buy rating.Talk Talk Telecom: Jefferies moves target price from 270p to 284p and maintains a buy recommendation. Credit Suisse raises target price from 200p to 275p and retains an outperform rating.Travis Perkins: Goldman Sachs downgrades from strong buy to buy with a target price of 1708p.Vedanta Resources: HSBC Holdings reduces target price from 1310p to 1280p and maintains its neutral rating.Vodafone Group: Jefferies shifts target price from 174p to 179p keeping a hold recommendation.Whitbread: Credit Suisse increases target price from 2760p to 2900p reiterating an outperform rating.William Hill: Nomura shifts target price from 333p to 339p and stays with its reduces rating. JP Morgan moves target price from 485p to 490p keeping an overweight rating.
More News
19 Mar 2024 09:21

LONDON BROKER RATINGS: Investec cuts ConvaTec; RBC raises Vistry

(Alliance News) - The following London-listed shares received analyst recommendations Tuesday morning:

Read more
18 Mar 2024 12:00

GSK unveils promising results from endometrial cancer trial

(Sharecast News) - GSK unveiled promising outcomes from a phase three trial of 'Jemperli', or dostarlimab, in treating primary advanced or recurrent endometrial cancer on Monday.

Read more
18 Mar 2024 08:47

TOP NEWS: Pfizer launches GBP2 billion sale of 8% stake in Haleon

(Alliance News) - Haleon PLC on Monday said Pfizer Inc plans to sell around GBP2 billion in Haleon shares, some of which will be bought back by Haleon.

Read more
18 Mar 2024 08:47

GSK says Jemperli combination gets good results for endometrial cancer

(Alliance News) - GSK PLC on Monday said a test of its Jemperli drug in combination with chemotherapy has shown it reduced the risk of death in patients with endometrial cancer by nearly a third.

Read more
7 Mar 2024 09:38

GSK observes positive data in Blenrep trial for blood cancer treatment

(Alliance News) - GSK PLC on Thursday announced positive results for Blenrep for the treatment of multiple myeloma.

Read more
7 Mar 2024 07:21

GSK reports more encouraging trial results for Blenrep

(Sharecast News) - GSK unveiled encouraging results from its 'DREAMM-8' phase three trial on Thursday, comparing the efficacy of 'Blenrep', or belantamab mafodotin, in combination with pomalidomide plus dexamethasone, or PomDex, against the standard treatment of bortezomib plus PomDex in relapsed or refractory multiple myeloma patients.

Read more
5 Mar 2024 11:03

GSK says ViiV's cabotegravir study supports longer HIV dose interval

(Alliance News) - GSK PLC on Tuesday celebrated study results from ViiV Healthcare Ltd, that showed an investigational formulation of cabotegravir can be dosed at four-month intervals.

Read more
5 Mar 2024 07:26

GSK's ViiV upbeat on ultra-long-acting HIV treatment study

(Sharecast News) - GSK announced on Tuesday that its specialist GIV joint venture with Pfizer and Shionogi, ViiV Healthcare, had reported encouraging results from its phase one clinical trial of an investigational formulation of cabotegravir, termed cabotegravir ultra long-acting (CAB-ULA).

Read more
29 Feb 2024 09:44

TOP NEWS: GSK avoids "protracted litigation" with Zantac settlement

(Alliance News) - GSK PLC on Thursday emphasised its commitment to science, as it reached another settlement in ongoing litigation over alleged links between its heartburn drug and cancer.

Read more
29 Feb 2024 07:22

GSK reaches settlement in another Zantac case

(Sharecast News) - GSK announced a confidential settlement with Boyd/Steenvoord, effectively resolving a case filed in California state court over its discontinued heartburn drug Zantac.

Read more
26 Feb 2024 08:25

GSK gonorrhoea treatment achieves efficacy endpoint in latest trial

(Alliance News) - GSK PLC on Monday announced positive results from the latest trial of its oral gonorrhoea treatment, showing it to be on par with intramuscular therapies.

Read more
26 Feb 2024 07:22

GSK reports positive results from gonorrhoea treatment trial

(Sharecast News) - GSK announced encouraging headline outcomes from its trial of gepotidacin, an oral antibiotic aiming to address uncomplicated urogenital gonorrhoea in adolescents and adults, on Monday.

Read more
21 Feb 2024 09:47

GSK reports encouraging results for ViiV's Cabenuva HIV treatment

(Alliance News) - GSK PLC on Wednesday said that its majority-owned company ViiV Healthcare had received positive interim data from ongoing trials of its injectable HIV treatment.

Read more
21 Feb 2024 07:22

GSK's ViiV sees success in latest HIV treatment trial

(Sharecast News) - GSK's specialist HIV unit ViiV Healthcare, which it owns in partnership with Pfizer and Shionogi, unveiled promising findings from the 'LATITUDE' phase three trial of its long-acting injectable HIV treatment Cabenuva on Wednesday.

Read more
20 Feb 2024 15:10

PRESS: AJ Bell founder to join Applied Nutrition ahead of IPO - Sky

(Alliance News) - Supplements maker Applied Nutrition, plotting a London stock market float, is to add AJ Bell PLC founder Andy Bell as its chair, Sky News reported on Tuesday.

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.